The authors regret that in the production of [Table 2](#tbl1){ref-type="table"} for this paper, information regarding data for ritonavir boosted drugs was omitted. An amended version of [Table 2](#tbl1){ref-type="table"} is now appearing.

The authors would like to apologise for any inconvenience this may have caused to the authors of this article and the readers of the journal.

###### 

A simple scheme to rank CSF-penetrating drugs or the CNS-penetration effectiveness (CPE) ranks, proposed by [@bib1]. Rank based on the drug physicochemical characteristics, measured CSF concentrations and CNS efficacy data extracted from publicly available information. Ritonavir boosted = r.

                      Low                 Intermediate          High
  ------------------- ------------------- --------------------- ------------------
  NRTIs               Tenofovir (PMPA)    Stavudine (d4T)       Zidovudine (AZT)
                      Didanosine (ddI)    Lamivudine (3TC)      Abacavir
                      Zalcitabine (ddC)   Emtricitabine (FTC)   
                                                                
  NNRTIs                                  Efavirenz             Delavirdine
                                                                Nevirapine
                                                                
  PIs                 Nelfinavir          Amprenavir            Amprenavir-r
                      Ritonavir           Indinavir             Indinavir-r
                      Saquinavir          Atazanavir            Lopinavir-r
                      Saquinavir-r        Atazanavir-r          Fosamprenavir-r
                      Tipranavir-r        Fosamprenavir         
                                                                
  Fusion inhibitors   Enfuvirtide                               
